1-7 of 7
Kim Chi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer

Eric Winquist, Sebastien J. Hotte, Kim Chi, Srikala Sridhar, Susan Ellard, Michael Ong, Nayyer Iqbal, Muhammad Salim, Urban Emmenegger, Joel R. Gingerich, Aly-Khan Lalani, Pierre Major, Christian Kollmannsberger, Steven Yip, Aaron Hansen, Daygen Finch, Christina Canil, James Hutchenreuther, Francisco Vera-Badillo, Martin Smoragiewicz, Michael Cabanero, Ming-Sound Tsao, Elie Ritch, Alexander W. Wyatt, Lesley Seymour
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (1): 45–55.
https://doi.org/10.1158/1078-0432.CCR-24-1612
Published: 06 January 2025
View article titled, Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer
Open the PDF for Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract PR09: Frequency and etiology of ctDNA-positive metastatic prostate cancer with BRCA2, ATM, or CDK12 mutations

Evan Warner, Steven Yip, Matti Annala, Gang Wang, Arkhjamil Angeles, Arshia Beigi, Elena Schönlau, Amanda Wong, Sinja Taavitsainen, Gillian Vandekerkhove, Kevin Beja, Matti Nykter, Daniel Khalaf, Kim Chi, Alexander Wyatt
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11_Supplement): PR09.
https://doi.org/10.1158/1557-3265.LiqBiop20-PR09
Published: 01 June 2020
View article titled, Abstract PR09: Frequency and etiology of ctDNA-positive metastatic prostate cancer with BRCA2, ATM, or CDK12 mutations
Journal Articles

Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c

Fred Saad, Sebastien Hotte, Scott North, Bernie Eigl, Kim Chi, Piotr Czaykowski, Lori Wood, Michael Pollak, Scott Berry, Jean-Baptiste Lattouf, Som D. Mukherjee, Martin Gleave, Eric Winquist
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (17): 5765–5773.
https://doi.org/10.1158/1078-0432.CCR-11-0859
Published: 01 September 2011
View article titled, Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c
Open the PDF for Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c in another window
Journal Articles

Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer

Amina Zoubeidi, Kim Chi, Martin Gleave
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (4): 1088–1093.
https://doi.org/10.1158/1078-0432.CCR-09-2917
Published: 15 February 2010
View article titled, Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer
Open the PDF for Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer in another window
Journal Articles

A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer

Anthony W. Tolcher, Kim Chi, John Kuhn, Martin Gleave, Amita Patnaik, Chris Takimoto, Garry Schwartz, Ian Thompson, Kristin Berg, Susan D'Aloisio, Nevin Murray, Stanley R. Frankel, Elzbieta Izbicka, Eric Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (10): 3854–3861.
https://doi.org/10.1158/1078-0432.CCR-04-2145
Published: 16 May 2005
View article titled, A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer
Open the PDF for A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer in another window
Journal Articles

Enhanced Radiation Sensitivity in Prostate Cancer by Inhibition of the Cell Survival Protein Clusterin

Tobias Zellweger, Kim Chi, Hideaki Miyake, Hans Adomat, Satoshi Kiyama, Kirsten Skov, Martin E. Gleave
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (10): 3276–3284.
Published: 01 October 2002
View article titled, Enhanced Radiation Sensitivity in Prostate Cancer by Inhibition of the Cell Survival Protein Clusterin
Open the PDF for Enhanced Radiation Sensitivity in Prostate Cancer by Inhibition of the Cell Survival Protein Clusterin in another window
Journal Articles

A Randomized Phase II and Pharmacokinetic Study of the Antisense Oligonucleotides ISIS 3521 and ISIS 5132 in Patients with Hormone-refractory Prostate Cancer

Anthony W. Tolcher, Leonard Reyno, Peter M. Venner, Scott D. Ernst, Malcolm Moore, Richard S. Geary, Kim Chi, Sean Hall, Wendy Walsh, Andrew Dorr, Elizabeth Eisenhauer
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (8): 2530–2535.
Published: 01 August 2002
View article titled, A Randomized Phase II and Pharmacokinetic Study of the Antisense Oligonucleotides ISIS 3521 and ISIS 5132 in Patients with Hormone-refractory Prostate Cancer
Open the PDF for A Randomized Phase II and Pharmacokinetic Study of the Antisense Oligonucleotides ISIS 3521 and ISIS 5132 in Patients with Hormone-refractory Prostate Cancer in another window